Pharmacokinetics/Pharmacodynamics (PK/PD) of Antimicrobials and Novel Agents
A workshop for graduate students, pharmacy students, and postdocs
Jacob K. McPherson
University of Houston College of Pharmacy
August 27, 2025
This workshop was inspired by a conversation
Between Dr. Cesar Arias, MD, PhD, and Dr. Brad spellberg, MD
Learning Objectives
- Describe the fundamental concepts of pharmacokinetics and pharmacodynamics (PK/PD).
- Discuss the design and utility of PK/PD studies, including hands-on applications using R programming.
- translate clinical PK/PD to dose optimization using R programming.
- Identify PK/PD considerations for new drug development.
If this workshop is insufficient,
I hope these resources from the NIH Clinical Center help!
Animal Scale Up and First-in-Human Studies
by Dr. Jerry Collins, PhD
Dose Selection and Optimization
by Dr. Yaning Wang, PhD
Drub Absorption and Bioavailability
by Dr. Jan H. Beumer, PharmD, PhD
Multicompartment Pharmacokinetic Modeling
by Dr. Scott r. Penzak, PharmD, FCP
Population Pharmacokinetics
by Dr. Robert R. Bies, PharmD, PhD
Pharmacodynamics in Drug Development
by Dr. James Doroshow, MD
Background Clinical Microbiology
Bacteriostatic vs. Bactericidal Activity
Minimum Inhibitory Concentrations (MIC)1
![]()
Bacteriostatic vs. Bactericidal Activity
Minimum Bactericidal Concentrations (MBC)2
![]()
Pharmacokinetics (PK) 101
ADME
Distribution
content
Non-Compartmental (NCA) vs. Compartmental Analysis (CA)
subtitle
content
One- vs. Multi-Compartment Models
subtitle
content
Pharmacokinetics/Pharmacodynamics (PK/PD) of Antimicrobials
The in vitro Hollow-Fiber Infection Model (HFIM)
The in vivo Animal Models of Infection
